Metastatic Prostate Cancer Drug Pipeline Analysis Report 2025

Studies suggest that approximately 50% of men who have been diagnosed with local prostate cancer will get metastatic cancer during their lifetime. Metastatic prostate cancer also called advanced prostate cancer occurs when cancer cells from the prostate gland spread to other body parts. This cancer can spread to lymph nodes outside the pelvis, bones, or other organs like the liver or lungs. This cancer is considered stage IV prostate cancer. Metastatic prostate cancer clinical trials are discovering new and innovative treatments. These studies test new metastatic prostate cancer therapeutics and treatment strategies offering patients access to novel therapies.

Report Coverage

The Metastatic Prostate Cancer Pipeline Report by the publisher gives comprehensive insights into metastatic prostate cancer disease emerging drugs currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for metastatic prostate cancer. The metastatic prostate cancer pipeline insight includes the analysis of over 100 pipeline drugs and 50+ companies . It will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from metastatic prostate cancer.

The detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration and ongoing metastatic prostate cancer pipeline development activities are covered in the report.

Metastatic Prostate Cancer Drug Pipeline Outlook

Metastatic prostate cancer, which is also called advanced prostate cancer is the spread of tumor cells from the prostate to other body parts, including lymph nodes or bones. It can also spread to organs such as the liver and lungs. The rare locations to which metastasis prostate cancer can spread include adrenal glands, breasts, kidneys, muscles, pancreas, brain, salivary glands, and others. Cancer cells break away from the original tumor and go to lymph vessels and may move through the body.

Treatment for metastatic prostate cancer depends on the stage of the cancer and includes hormone therapy, chemotherapy, radiotherapy, targeted drugs, radioisotope therapy, and steroids among others. Androgen deprivation therapy (ADT) is a type of hormone therapy. The therapy includes taking metastatic prostate cancer drugs to lower levels of androgens or may include surgery to remove the testicles, as they often fuel the growth of prostate cancer cells.

Several companies and institutes are developing innovative metastatic prostate cancer drug candidates to manage the condition. For instance, Curium US LLC is currently doing a phase III trial of Abiraterone with Prednisone or Enzalutamide. The study is being conducted to evaluate the safety and efficacy of 177Lu-PSMA-I&T versus hormone therapy in patients with metastatic castration-resistant prostate cancer. Drugs like olaparib and rucaparib target cancer cells with BRCA1 or BRCA2 mutations are also the areas of research. The development of innovative treatments has impacted the pipeline landscape significantly.

Metastatic Prostate Cancer - Drug Pipeline Therapeutic Assessment

This section of the report covers the analysis of metastatic prostate cancer drugs based on several segmentations including:

By Phase

The pipeline assessment report covers 50+ drug analyses based on phase.

• Late-Stage Products (Phase 3 and Phase 4)
• Mid-Stage Products (Phase 2)
• Early-Stage Products (Phase I)
• Preclinical and Discovery Stage Products

By Drug Class

The metastatic prostate cancer therapeutic assessment covers 50+ drug analyses based on drug classes:

• Recombinant Fusion Proteins
• Small Molecule
• Monoclonal Antibody
• Peptide
• Polymer
• Gene Therapy

By Route of Administration

The metastatic prostate cancer clinical assessment covers 50+ drug analyses based on the route of administration.

• Oral
• Parenteral
• Others

Metastatic Prostate Cancer - Pipeline Assessment Segmentation, By Phases

The metastatic prostate cancer report assessment covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to analysis, phase II covers a major share of the total clinical trials for metastatic prostate cancer pipeline drugs, having 800+ drugs in phase II.

Metastatic Prostate Cancer - Pipeline Assessment Segmentation, By Drug Classes

The drug molecules categories covered under metastatic prostate cancer pipeline analysis include recombinant fusion proteins, small molecules, monoclonal antibodies, peptides, polymer, and gene therapy. According to a phase II study conducted by Johns Hopkins Kimmel Cancer Center and Bloomberg~Kimmel Institute for Cancer Immunotherapy, a monoclonal antibody called enoblituzumab, is safe in men with aggressive prostate cancer and induces clinical activity against cancer throughout the body. It will be the first promising antibody-based immunotherapy agent to treat prostate cancer, if confirmed in additional studies. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for metastatic prostate cancer.

Metastatic Prostate Cancer Clinical Trials Assessment - Competitive Dynamics

The metastatic prostate cancer report insights cover the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in metastatic prostate cancer clinical trials:

• Curium US LLC
• SpectronRX
• AstraZeneca
• Bayer
• Sanofi
• Janssen Pharmaceutica
• Cleveland BioLabs
• Aurelius Omlin
• Bristol-Myers Squibb
• Janssen Biotech, Inc.
• Novartis
• Pfizer
• Sorrento Therapeutics, Inc.
• Merck Sharp & Dohme LLC
• Others

Metastatic Prostate Cancer - Emerging Drugs Profile

This section covers the detailed analysis of each drug under multiple phases including phase I, phase II, phase III, phase IV, and metastatic prostate cancer therapeutic drugs. It covers necessary details such as product description, study type, drug class, mode of administration, and recruitment status of upcoming metastatic prostate cancer drug candidates.

Drug: Aflibercept

The trial is designed to evaluate the overall survival improvement with aflibercept compared to placebo in patients who are receiving prednisone for metastatic androgen-independent prostate cancer. The trial is sponsored by Sanofi and is currently under phase III.

Drug: Carboplatin

The objective of the study is to demonstrate the success of carboplatin in patients with advanced metastatic castration-resistant prostate cancer and DNA repair defects. The trial is sponsored by Aurelius Omlin and is currently under phase II.

Drug: Radium-223 dichloride

Bayer is developing this metastatic prostate cancer drug candidate and is currently under phase III. The study is being conducted to evaluate the safety and efficacy of multiple doses of Ra-223 dichloride in patients with CRPC metastatic to the bone.

Reasons To Buy This Report

The Metastatic Prostate Cancer Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for metastatic prostate cancer. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within metastatic prostate cancer pipeline insight.

Key Questions Answered in the Metastatic Prostate Cancer - Pipeline Assessment Report

• What is the current landscape of metastatic prostate cancer pipeline drugs?
• Which companies/institutions are developing metastatic prostate cancer emerging drugs?
• How many phase II drugs are currently present in metastatic prostate cancer pipeline drugs?
• Which company is leading the metastatic prostate cancer pipeline development activities?
• What is the current metastatic prostate cancer therapeutic assessment?
• What are the opportunities and challenges present in the metastatic prostate cancer drug pipeline landscape?
• What is the efficacy and safety profile of metastatic prostate cancer pipeline drugs?
• Which companies/institutions are involved in metastatic prostate cancer collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in metastatic prostate cancer?

This product will be delivered within 3-5 business days.